外显子组测序
外显子组
产前诊断
医学
医学遗传学
遗传咨询
遗传学
怀孕
生物信息学
维加维斯
人类遗传学
基因检测
儿科
生物
胎儿
临床意义
产量(工程)
先天性畸形
拷贝数变化
诊断试验
突变
作者
Katia Margiotti,Marco Fabiani,Antonella Cima,Francesca Monaco,Chiara Alì,Antonietta Barone,Antonella Viola,Mauro Truglio,Costanza Zangheri,Alvaro Mesoraca,Claudio Giorlandino
摘要
Prenatal exome sequencing (ES) is increasingly requested in pregnancies without ultrasound-detected structural anomalies, yet its diagnostic yield and clinical value in this low-risk setting remain incompletely defined. We reviewed 209 consecutive prenatal trio-ES cases performed in structurally normal pregnancies over a 3 year period. Variants were classified according to ACMG/AMP guidelines, and reporting was restricted to pathogenic (P) or likely pathogenic (LP) variants associated with childhood-onset disorders and/or medically actionable secondary findings. P/LP variants were detected in 30 of 211 fetuses (overall P/LP detection rate 14.2%; 95% CI 10.1%-19.6%). After reclassifying three adult-onset cancer-predisposition findings (BRCA2, MSH6, SDHD) as parental secondary findings and excluding them from the reportable set, the diagnostic yield was 27/211 (12.8%; 95% CI 8.9%-18.0%); this reportable definition is used throughout. Inherited variants predominated over de novo events (25/30; 83.3%), and autosomal dominant conditions were the most frequent category. Seven of the 30 positive cases involved genes on the ACMG SF v3.3 list. Pregnancy termination was elected in 2 of 30 positive cases (6.7%). In structurally normal pregnancies, the value of prenatal trio-ES lies less in detectability than in the nature of its findings mostly inherited, often incompletely penetrant and in their clinical and ethical implications: informing genetic counseling; guiding postnatal surveillance; facilitating familial cascade testing; identifying medically actionable secondary findings; and raising distinct questions of consent and the future child's autonomy.
科研通智能强力驱动
Strongly Powered by AbleSci AI